Home
NICE Guidance
Conditions and diseases
Cardiovascular conditions
Stroke and transient ischaemic attack
Stroke and transient ischaemic attack
Explore
Register as a stakeholder
Show sections
Research Recommendations
Upper limb electrical stimulation:- What is the clinical and cost effectiveness of electrical stimulation (ES) as an adjunct ...
July 2013
Intensive rehabilitation after stroke:- In people after stroke what is the clinical and cost effectiveness of intensive rehab...
July 2013
Neuropsychological therapies:- Which cognitive and which emotional interventions provide better outcomes for identified subgr...
July 2013
Shoulder pain:- Which people with a weak arm after stroke are at risk of developing shoulder pain? What management strategies...
July 2013
Offer electromechanical gait training to people after stroke only in the context of a research study.
July 2013
What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifa...
October 2014
What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using ...
October 2014
What is the effectiveness of statin therapy in older people?
October 2014
What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?
October 2014
What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared wit...
October 2014
Full List
Shared Learning
Developing and implementing a set of outcome measures incorporating NICE Standards across the whole stroke care pathway in Greater Manchester
December 2016
Nurse-led care for patients after a TIA
January 2012
Using Quality Standards on Stroke in Quality Accounts
January 2012
Monitoring of stroke care within the North West England
January 2012
Do not do
Do not routinely offer wrist and hand splints to people with upper limb weakness after stroke.
June 2013
Do not routinely offer people with stroke electrical stimulation for their hand and arm.
June 2013
Do not use a risk assessment tool to assess CVD risk in people with type 1 diabetes.
July 2014
Do not use a risk assessment tool to assess cardiovascular disease (CVD) risk in people with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 and/or albuminuria[4]. These people are at increased risk of CVD.
July 2014
Do not use a risk assessment tool for people with pre-existing cardiovascular disease (CVD).
July 2014
Do not advise any of the following to take plant stanols or sterols for the prevention of CVD: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes
July 2014
Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin.
July 2014
Do not stop statins because of an increase in blood glucose level or HbA1c.
July 2014
Do not offer coenzyme Q10 or vitamin D to increase adherence to statin treatment.
July 2014
Do not routinely offer fibrates for the prevention of CVD to any of the following: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes.
July 2014
Full List
Guidance
Resources
Savings and productivity
Local practice